immunotherapy

Research in Review

Immune Checkpoint Inhibitor New Standard of Care for MSI-H Metastatic Colorectal Cancer

01/25/2017

JCP Editors

The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...

The...

01/25/2017

Journal of Clinical Pathways

Research in Review

New Treatment Effective for B-Cell Precursor ALL in Pediatric Patients

11/17/2016

JCP Editors

Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...

...

11/17/2016

Journal of Clinical Pathways

Research in Review

Immunotherapies May Pose Severe Heart Risk

11/04/2016

JCP Editors

Researchers have identified a serious and potentially fatal adverse event associated with immunology drugs, according to a study published in the New England Journal of Medicine. Immune checkpoint inhibitors have...

...

11/04/2016

Journal of Clinical Pathways

Research in Review

Immunotherapy Drug Improves Overall Survival in Patients With NSCLC

12/30/2015

JCP Editors

Favorable results for pembrolizumab, a PD-1/PD-L1 inhibitor only recently approved for the treatment of non-small-cell lung cancer (NSCLC), were found in a trial comparing the drug’s effectiveness to that of the...

...

12/30/2015

Journal of Clinical Pathways

Overall Survival for Progressive Bladder Cancer Improved with Personalized Peptide Vaccination

12/01/2015

JCP Editors

A new immunotherapy may help to improve outcomes of patients with metastatic bladder cancer, according to the results of a Phase II study. Bladder cancer is one of the most common and deadly forms of cancer for men...

A new...

12/01/2015

Journal of Clinical Pathways

Research in Review

Improved Outcomes for NSCLC Patients with Immunotherapy versus Chemotherapy

10/15/2015

JCP Editors

Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with...

...

10/15/2015

Journal of Clinical Pathways